Supplementary Materials

THMs	Measured Value ^a (ng/mL)	Standard Value ^b (ng/mL)	Reference Type	Coincidence (%)
Cr	6.76 ± 0.13	6.99 (5.24-8.74)	Serum ^c	96.76
Cd	4.95 ± 0.09	4.92 (3.94-5.90)	Serum ^c	100.59
Pb	3.68 ± 0.03	3.83 ± 0.18	Hair ^d	101.03
As	19.90 ± 0.55	19.70 (15.80–23.60)	Serum ^c	95.98

Table S1. Measured and standard concentrations of the certified reference materials.

^a The measured value is the mean and standard deviation for three repeated measurements. ^b Standard values are provided by the company. c ClinChek® Serum Controls (trace elements level II, REF 8881, EVISA). ^d Human Hair Certified Reference Material (GBW09101b, China).

Table S2. Limit and	precision of detectior	n for four toxic heav	y metals (THMs).
---------------------	------------------------	-----------------------	------------------

	Instrument	Dilutio	Method Detection	Repeatability	Reproducibility	
THMs	Detection Limit (ng/mL)	n Factor	Limit (ng/mL)	Rel. Repeat. SD #	Rel. Repro. SD*	
Cr	0.002	20	0.04	1.86%	2.38%	
Cd	0.003	20	0.06	1.88%	2.32%	
Pb	0.010	20	0.20	0.89%	2.24%	
As	0.016	20	0.32	2.77%	3.70%	

[#] Relative repeatability standard deviation: calculated by extracting 3 measurements from same day. * Relative reproducibility standard deviation: calculated by extracting 3 measurements from 3 different days.

Table S3. Main characteristics of included studies in the meta-analysis.

N.	Arathere	Druceb	Deskliched	A	C		Sample size		TING	NOS score
No.	Authora	Drug ^b Published year Area Geographic area Sample ty		Sample type	Case	control	THMs	NO5 score		
[1]	Guo et al.	1	2013	China	Asia	serum	119	126	Cr, Cd, Pb, As	9
[2]	Arinola et al1	0	2010	Nigeria	Africa	plasma	15	20	Cr, Cd, Pb	7
	Arinola et al2	1	2010	Nigeria	Africa	plasma	20	20	Cr, Cd, Pb	7
[3]	Cai et al1	0	2015	China	Asia	serum	61	61	Cr, Cd, Pb, As	8
	Cai et al2	0	2015	China	Asia	serum	50	49	Cr, Cd, Pb, As	8
[4]	Li et al.	1	2018	China	Asia	serum	158	669	Cr, As	8

[5]	P.C. Stanley et al1	0	2002	Nigeria	Africa	serum	20	20	Cd, Pb	6
	P.C. Stanley et al2	1	2002	Nigeria	Africa	serum	20	20	Cd, Pb	6
	P.C. Stanley et al3	1	2002	Nigeria	Africa	serum	20	20	Cd, Pb	6
[6]	Present study	0	-	China	Asia	serum	95	95	Cr, Cd, Pb, As	9

^a Arinola et al._1 The schizophrenic patients were newly diagnosed and not taking antipsychotic drugs. Arinola et al._2 The schizophrenic patients had used antipsychotic drugs for at least 2 weeks. Cai et al._1 The case and control were from a training set. Cai et al._2 The case and control were from a test set. P.C. Stanley et al._1 The schizophrenic patients before the start of treatment. P.C. Stanley et al._2 The schizophrenic patients at 3 weeks after treatment. P.C. Stanley et al._3 The schizophrenic patients at 7 weeks after treatment. ^b 0: patients with schizophrenia were not treated with antipsychotic drugs. 1: patients with schizophrenia were treated with antipsychotic drugs.

THMs	Groups	No of studios	Samp	ole size	Test of	association	Test of he	terogeneity
IHMS		No. of studies	Case	Control	SMD	95%CI	I^2	р
	Overall	5	518	1020	0.3246	0.0166-0.6326	83.0%	< 0.01
Cr	Drug = 0	3	211	225	0.3134	-0.2770-0.9038	88.2%	0.7640
	Drug = 1	3	297	815	0.4063	0.2662-0.5464	0.0%	0.7640
	Overall	6	538	1040	-0.0357	-0.4812 - 0.4098	92.6%	< 0.01
Cd	Drug = 0	4	241	245	0.2796	-0.2488 - 0.8079	86.2%	0.0070
	Drug = 1	4	317	835	-0.3763	-0.9452-0.1927	91.1%	0.0978
	Overall	6	538	1040	0.2537	-0.2108-0.7183	93.5%	< 0.01
Pb	Drug = 0	4	241	245	0.4064	0.1371-0.6757	47.9%	0.0007
	Drug = 1	4	317	835	0.0240	-0.7033-0.7512	95.0%	0.3337
	Overall	4	483	1000	0.4459	-1.1994-2.0912	99.4%	< 0.01
As	Drug = 0	2	206	205	-0.1397	-0.3889-0.1095	99.8%	0.4560
	Drug = 1	2	277	795	1.2972	-2.4727-5.0672	37.4%	0.4560

Table S4. Results of meta-analysis of 4 THMs.

Reference

1. Guo, J.; Zeng, J.; Yan, L.L.; Qiu, J.Y.; Feng, F.B.; Wang, J.Y. Quantitative detection and analysis of 41 kinds of trace elements in serum of patients with schizophrenia. *Clin J Med Offic.* **2013**, *41*, 44–26.

2. Arinola, G., B.; Idonije, K.; Akinlade, and O. Ihenyen. Essential trace metals and heavy metals in newly diagnosed schizophrenic patients and those on anti-psychotic medication. *J Res Med Sci.* 2010, *15*, 245–9.

3. Cai, L., T.; Chen, J.; Yang, K.; Zhou, X.; Yan, W.; Chen, L.; Sun, L.; Li, S.; Qin, P.; Wang, et al. Serum trace element differences between Schizophrenia patients and controls in the Han Chinese population. *Sci Rep.* 2015, *5*, 15013.

4. Li, Z.; Liu, Y.M.; Li, X.; Ju, W. Wu, G.R.; Yang, X.M.; Fu, X.F. Gao, X.B. Association of Elements with Schizophrenia and Intervention of Selenium Supplements. *Biol Trace Elem Res.* 2018, 183, 16–21.

5. Stanley, P.C.; V.C. Wakwe. Toxic trace metals in the mentally ill patients. Niger Postgrad Med J. 2002. 9, 199–204.





Figure S1. Forest plot of subgroup analysis stratified by whether the patients with schizophrenia treated with antipsychotic drugs (without present study). Overall pooled prevalence was calculated by random-effects module. Horizontal bars show 95% CIs. drug = 1, patients with schizophrenia were treated with antipsychotic drugs. drug = 0, patients with schizophrenia were not treated with antipsychotic drugs.



 Omitting Liet al.
 0.33
 [0.16, 0.36]

 Omitting Arinola et al._1
 0.17
 [-0.30; 0.65]

 Omitting Cai et al._2
 0.21
 [-0.28; 0.70]

 Omitting Cai et al._2
 0.25
 [-0.26; 0.76]

 Omitting P.C.Stanley et al._1
 0.20
 [-0.28; 0.69]

 Omitting P.C.Stanley et al._2
 0.24
 [-0.25; 0.74]

 Omitting Present study
 0.24
 [-0.27; 0.75]

 Random effects model
 0.25
 [-0.21; 0.72]

 0.24
 [-0.27; 0.75]
 Omitting Present study
 0.63
 [-1.40; 2.67]

 0.25
 [-0.21; 0.72]
 Random effects model
 0.45
 [-1.20; 2.09]

 5
 0
 0.5
 -2
 -1
 0
 1
 2

.

-0.27 [-0.58; 0.04]

Omitting Li et al.

Figure S2. Sensitivity analysis through deletion of one study at a time to reflect the influence of the individual dataset to the pooled SMDs of the THM concentrations in patients with schizophrenia and healthy controls.

Cr

Cd